doxazosin has been researched along with bisoprolol in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (22.73) | 29.6817 |
| 2010's | 15 (68.18) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brown, MJ; Deary, AJ; Foo, RS; Haydock, SF; Murfet, H; Schumann, AL | 1 |
| Boj, M; Camprubí, M; Hernandez-Flix, S; Solà, R | 1 |
| Dobrokhod, AS; Kushnir, SM; Radchenko, GD; Sirenko, YM; Torbas, OO | 1 |
| Brown, MJ; Caulfield, MJ; Cruickshank, JK; Ford, I; MacDonald, TM; Mackenzie, I; McInnes, G; Morant, S; Padmanabhan, S; Salsbury, J; Sever, P; Webb, DJ; Williams, B | 1 |
| Bakris, GL; Sternlicht, H | 1 |
| Huynh, K | 1 |
| Widimský, J | 1 |
| Rosenberg, M; Stephens, E | 1 |
| Divisón Garrote, JA; Escobar Cervantes, C | 1 |
| Boutari, C; Doumas, M; Imprialos, K; Karagiannis, A; Stavropoulos, K | 1 |
| Douma, S; Gavriilaki, E; Gkaliagkousi, E; Triantafyllou, A | 1 |
| Dale, A; Goldacre, B; Hartley, P | 1 |
| Brown, MJ; MacDonald, TM; Morant, SV; Williams, B | 1 |
| Kaysin, A; Mounsey, A | 1 |
| Allan, GM; Garrison, S; Turgeon, R | 1 |
| Brown, MJ; Caulfield, MJ; Cruickshank, JK; Ford, I; MacDonald, TM; Mackenzie, IS; McInnes, GT; Morant, SV; Padmanabhan, S; Salsbury, J; Sever, P; Webb, DJ; Williams, B | 1 |
| Doumas, M; Imprialos, KP; Kallistratos, MS; Manolis, AJ | 1 |
| Böhm, M; Götzinger, F; Hohl, M; Hübner, U; Lauder, L; Lehnert, U; Mahfoud, F; Meyer, MR; Schneider, C; Sevimli, Ö; Tokcan, M; Wagmann, L | 1 |
3 review(s) available for doxazosin and bisoprolol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Three drugs and still hypertensive: what's left?
Topics: Antihypertensive Agents; Bisoprolol; Blood Pressure; Doxazosin; Drug Therapy, Combination; Humans; Hypertension; Potassium; Spironolactone | 2016 |
Recent advances in understanding and managing resistant/refractory hypertension.
Topics: Antihypertensive Agents; Bisoprolol; Catheters; Clinical Trials as Topic; Clonidine; Denervation; Doxazosin; Humans; Hypertension; Kidney; Spironolactone | 2020 |
5 trial(s) available for doxazosin and bisoprolol
| Article | Year |
|---|---|
Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bendroflumethiazide; Bisoprolol; Blood Pressure; Calcium Channel Blockers; Cross-Over Studies; Diuretics; Double-Blind Method; Doxazosin; Female; Heart Rate; Humans; Hypertension; Lisinopril; Male; Middle Aged; Natriuretic Peptide, Brain; Renin-Angiotensin System; Sodium Chloride Symporter Inhibitors | 2002 |
Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Bisoprolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Chi-Square Distribution; Diuretics; Doxazosin; Drug Combinations; Drug Therapy, Combination; Electrocardiography; Female; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Middle Aged; Pulse Wave Analysis; Severity of Illness Index; Time Factors; Treatment Outcome; Ukraine; Vascular Stiffness | 2013 |
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; Cross-Over Studies; Double-Blind Method; Doxazosin; Female; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome | 2015 |
[PATHWAY-2 Study: spironolactone vs placebo, bisoprolol and doxazosin to determine optimal treatment of resistant hypertension. Spironolactone high effective in lowering blood pressure in drug resistant hypertension].
Topics: Antihypertensive Agents; Bisoprolol; Blood Pressure; Diuretics; Doxazosin; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Spironolactone | 2015 |
PURLs: Resistant hypertension? Time to consider this fourth-line drug.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bisoprolol; Doxazosin; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome | 2016 |
14 other study(ies) available for doxazosin and bisoprolol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Silica in oral drugs as a possible sarcoidosis-inducing antigen.
Topics: Administration, Oral; Antigens; Antihypertensive Agents; Bisoprolol; Causality; Chemistry, Pharmaceutical; Doxazosin; Humans; Hypertension; Male; Middle Aged; Pharmaceutical Vehicles; Sarcoidosis, Pulmonary; Silicon Dioxide; Tetrazoles; Valine; Valsartan | 2009 |
Spironolactone for resistant hypertension--hard to resist?
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazosin; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2015 |
Hypertension: PATHWAY to improving the treatment of drug-resistant hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazosin; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2015 |
ACP Journal Club. In resistant hypertension, add-on spironolactone reduced SBP more than placebo, doxazosin, or bisoprolol over 12 wk.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazosin; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2016 |
[Spironolactone versus placebo, bisoprolol and doxazosin to determine the optimal treatment for drug-resistant hypertension].
Topics: Antihypertensive Agents; Bisoprolol; Doxazosin; Drug Therapy, Combination; Humans; Hypertension; Spironolactone | 2016 |
PATHWAY-2: spironolactone for resistant hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazosin; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2016 |
PATHWAY-2: spironolactone for resistant hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazosin; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2016 |
PATHWAY-2: spironolactone for resistant hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazosin; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2016 |
PATHWAY-2: spironolactone for resistant hypertension - Authors' reply.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazosin; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2016 |
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.
Topics: Aldosterone; Amiloride; Antihypertensive Agents; Bisoprolol; Blood Pressure; Doxazosin; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Randomized Controlled Trials as Topic; Spironolactone | 2018 |
Efficacy of Antihypertensive Drugs of Different Classes After Renal Denervation in Spontaneously Hypertensive Rats.
Topics: Aldosterone; Amlodipine; Animals; Antihypertensive Agents; Bisoprolol; Blood Pressure; Cardiomyopathies; Denervation; Doxazosin; Hydrochlorothiazide; Hypertension; Kidney; Male; Rats; Rats, Inbred SHR; Renin; Sympathectomy | 2023 |